Navigation Links
Pinnacle Biologics Announces Opening of Executive Offices in Bannockburn, Illinois and the Addition of Sandra Miller to the Board of Directors
Date:7/1/2008

BANNOCKBURN, Ill., July 1 /PRNewswire/ -- Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company today announced it has entered into a lease agreement to establish its headquarters in Bannockburn, Illinois.

"This is another key milestone reached by Pinnacle to bring the top management together, consolidate resources in one office, and give additional momentum to the future expansion of the company," said Guillermo Herrera, chairman of the board of Pinnacle Biologics.

James R. Miller, President & CEO stated, "This is a pivotal strategic decision made by the Pinnacle Founders. Now that we have the headquarters staff consolidated in Bannockburn, Ill., we will be able to optimize our resources in Maryland and The Netherlands."

The company today further announced it has appointed Sandra (Sandy) Miller, a Principal of Hewitt Associates, to the Board of Directors. Sandy has over 20 years of experience in human resources consulting.

"The founders of Pinnacle welcome Sandy to the Board of Directors," said Mr. Herrera, chairman of the board of Pinnacle Biologics. "Sandy brings a breadth of experience to Pinnacle including her human resources and compensation knowledge, global talent management expertise, and overall business acumen."

Sandy commented, "Pinnacle's innovative approach to worldwide commercialization of biotechnology/pharmaceutical products is a demonstration of the strength and experience of the seasoned veterans leading this organization. I am pleased to work with all of them."

About Pinnacle Biologics

Founded in 2007 by former Abbott Laboratories executives Guillermo Herrera, James Miller, and Viren Grover, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.

Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billing and collections), pharmacovigilence, product safety, market research and administrative services.
Website: http://www.pinnaclebiologics.com

COMPANY CONTACT:

James R. Miller, Pinnacle

President & CEO

1 (240) 372-4599


'/>"/>
SOURCE Pinnacle Biologics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pinnacle Biologics Announces Logistics Services Agreement With the Movianto Group
2. Pinnacle Biologics Announces Contract With Chiltern
3. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
4. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
5. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
6. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
7. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
8. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
9. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
10. MedImmune Submits Biologics License Application to FDA for Motavizumab
11. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and SAN FRANCISCO , Feb. 23, ... medicine company, and Beyond Type 1, a not-for-profit advocacy ... diabetes, today announced a grant from Beyond Type 1 ... for type 1 and other insulin-requiring diabetes.  ... developing innovative stem cell-derived cell replacement therapies with a ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... Kendall Research Systems, LLC (KRS) clinical development program. KRS is a ... technology for research and clinical applications. The terms of the transaction were not ...
(Date:2/22/2017)... Scientists propose in Nature blocking a molecule ... maybe other lysosomal storage diseases as a possible treatment ... An international research team led by ... investigators from the University of L├╝beck in ... study was conducted in mouse models of lysosomal storage ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... tech innovators, engineers, and scientists from around the world, is pleased to announce ... February 22 and 23, 2017. This premier, online-only conference focused on the development ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
Breaking Biology News(10 mins):